Current Approaches to Systemic Management of Regionally Advanced or Metastatic Melanoma

SELF STUDY / ENDURING - ESTIMATED TIME TO COMPLETE ACTIVITY: 40 Minutes

Overview

Participants will explore the latest systemic management strategies for regionally advanced or metastatic melanoma, focusing on the efficacy of targeted therapies and immunotherapies in addressing specific genetic mutations and enhancing patient outcomes. The session will also tackle the complexities of managing immune-related adverse events (IRAEs), particularly those associated with immune checkpoint inhibitors, emphasizing the challenges these toxicities present in clinical practice.

Target Audience

This CME initiative was designed for oncologists, surgeons, radiation oncologists, NPs, PAs, pharmacists, nurses, and other healthcare professionals involved in the treatment of patients with cancer.

Learning Objectives

  1. Discuss current approaches to systemic treatment options for adults with regionally advanced or metastatic melanoma
  2. Review the spectrum of mutations associated with regionally advanced or metastatic melanoma 
  3. Identify the common and more unusual treatment-associated toxicities in symptomatic patients
  4. Discuss management strategies for common and rare toxicities related to checkpoint inhibitor therapy 

 

Course summary
Available credit: 
  • 0.75 AMA PRA Category 1 Credit™

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.

    Horizon CME designates this Enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Course opens: 
09/05/2025
Course expires: 
09/05/2026
Cost:
$0.00
Rating: 
0

Faculty

Wolfram Samlowski, MD, FACP

Medical Oncologist
Comprehensive Cancer Centers of Nevada 
Las Vegas, NV
Clinical Professor of Medicine, UNLV

Wolfram Samlowski, MD, is a medical oncologist at the Comprehensive Cancer Centers of Nevada in Las Vegas, a clinical professor of medicine at the University of Nevada School of Medicine (Reno), and UNLV. He is a Health Economics and Outcomes researcher for Ontada (Mckesson). His clinical specialties are malignant melanoma and other advanced skin cancers, renal cancer, and sarcoma. He has expertise in targeted therapy and cancer immunotherapy using cytokines and checkpoint inhibitor antibodies. 

He received his MD from the Ohio State University in Columbus, Ohio, and completed his residency in internal medicine at Wayne State University in Detroit, Michigan. He completed a fellowship in hematology/oncology at the University of Utah in Salt Lake City, Utah. He is a physician at Comprehensive Cancer Centers of Nevada (Las Vegas). He has an academic appointment of Clinical Professor at both the University of Nevada (Reno) and UNLV.

Disclosures:

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Horizon CME (HCME) ensures that continuing education activities are balanced, independent, objective, and scientifically rigorous. 

All persons in a position to influence the content of an accredited continuing education activity provided by Horizon CME are required to disclose to HCME any relevant financial relationships with ineligible companies within the past 24 months. All reported relevant financial relationships have been mitigated by Horizon CME.

Wolfram Samlowski, MD, FACP declares the following financial relationships:

Speakers Bureau: Regeneron (CSCC, BCC), BMS (active) – melanoma

Advisory Boards: 
Sun Pharm (active) – BCC
Eisai – this relationship has ended
Replimune (active) – melanoma (RP1)

Consulting Fee: Ontada (active) – real world patient outcome analysis
 

Available Credit

  • 0.75 AMA PRA Category 1 Credit™

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.

    Horizon CME designates this Enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Price

Cost:
$0.00
Please login or register to take this course.

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. Participate in the online activity.
  3. Complete the post-test
  4. Submit the evaluation form

DISCLAIMER:

This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

Required Hardware/software

Access to the internet is required.

Supported Browsers:

Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above

Google Chrome 28.0+ for Windows, Mac OS, or Linux

Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux

Safari 6.0+ for Mac OSX 10.7 and above

 

Supported Phones & Tablets:

 Android 4.0.3 and above

iPhone/iPad with iOS 6.1 or above